MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE VIIA
The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) polypeptides and albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to 5'part of a cDNA cod...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | UWE LIEBING U STEFAN SCHULTE S THOMAS WEIMER T ULRICH KRONTHALER U WILFRIED WORMSBAECHER W WIEGAND LANG W |
| description | The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) polypeptides and albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to 5'part of a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting increased specific activity and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HK1129421A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HK1129421A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HK1129421A13</originalsourceid><addsrcrecordid>eNrjZLD19XfxdPN0dVFw9nd0D_VxDPH091Nwc3QO8Q9SCPP0cVQI9wzxUHCNCHH1cwGq8nD0cdP18XRzBUp6OvIwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkngPb0NDI0sTI0NHQ2MilAAAvospEA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE VIIA</title><source>esp@cenet</source><creator>UWE LIEBING U ; STEFAN SCHULTE S ; THOMAS WEIMER T ; ULRICH KRONTHALER U ; WILFRIED WORMSBAECHER W ; WIEGAND LANG W</creator><creatorcontrib>UWE LIEBING U ; STEFAN SCHULTE S ; THOMAS WEIMER T ; ULRICH KRONTHALER U ; WILFRIED WORMSBAECHER W ; WIEGAND LANG W</creatorcontrib><description>The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) polypeptides and albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to 5'part of a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting increased specific activity and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150306&DB=EPODOC&CC=HK&NR=1129421A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150306&DB=EPODOC&CC=HK&NR=1129421A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>UWE LIEBING U</creatorcontrib><creatorcontrib>STEFAN SCHULTE S</creatorcontrib><creatorcontrib>THOMAS WEIMER T</creatorcontrib><creatorcontrib>ULRICH KRONTHALER U</creatorcontrib><creatorcontrib>WILFRIED WORMSBAECHER W</creatorcontrib><creatorcontrib>WIEGAND LANG W</creatorcontrib><title>MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE VIIA</title><description>The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) polypeptides and albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to 5'part of a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting increased specific activity and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLD19XfxdPN0dVFw9nd0D_VxDPH091Nwc3QO8Q9SCPP0cVQI9wzxUHCNCHH1cwGq8nD0cdP18XRzBUp6OvIwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkngPb0NDI0sTI0NHQ2MilAAAvospEA</recordid><startdate>20150306</startdate><enddate>20150306</enddate><creator>UWE LIEBING U</creator><creator>STEFAN SCHULTE S</creator><creator>THOMAS WEIMER T</creator><creator>ULRICH KRONTHALER U</creator><creator>WILFRIED WORMSBAECHER W</creator><creator>WIEGAND LANG W</creator><scope>EVB</scope></search><sort><creationdate>20150306</creationdate><title>MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE VIIA</title><author>UWE LIEBING U ; STEFAN SCHULTE S ; THOMAS WEIMER T ; ULRICH KRONTHALER U ; WILFRIED WORMSBAECHER W ; WIEGAND LANG W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HK1129421A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2015</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>UWE LIEBING U</creatorcontrib><creatorcontrib>STEFAN SCHULTE S</creatorcontrib><creatorcontrib>THOMAS WEIMER T</creatorcontrib><creatorcontrib>ULRICH KRONTHALER U</creatorcontrib><creatorcontrib>WILFRIED WORMSBAECHER W</creatorcontrib><creatorcontrib>WIEGAND LANG W</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>UWE LIEBING U</au><au>STEFAN SCHULTE S</au><au>THOMAS WEIMER T</au><au>ULRICH KRONTHALER U</au><au>WILFRIED WORMSBAECHER W</au><au>WIEGAND LANG W</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE VIIA</title><date>2015-03-06</date><risdate>2015</risdate><abstract>The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) polypeptides and albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to 5'part of a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting increased specific activity and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_HK1129421A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE VIIA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A30%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=UWE%20LIEBING%20U&rft.date=2015-03-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHK1129421A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |